



SMITHS GROUP FACT SHEET FY2019

MAKING A SAFER, MORE EFFICIENT AND BETTER CONNECTED WORLD SMITHS IS A LEADING INDUSTRIAL TECHNOLOGY COMPANY





BY EXECUTING ON OUR STRATEGY, WE ARE CONFIDENT WE WILL ACHIEVE OUR MEDIUM TERM AMBITION:

	FY2019	AMBITION
PORTFOLIO STRENGTH ¹	>90% (90%+
VITALITY INDEX ²	13% (~20%
STOCK TURNS ²	3.4x (→ ~6x
AFTERMARKET % ^{1,3}	49% (→ 50%+

	FY2019	AMBITION
UNDERLYING REVENUE GROWTH ¹	+3%	Outperform our chosen markets
OPERATING MARGIN ¹	17.1%	18-20%
ROCE ²	14.4%	16-18%
WC % SALES ²	26%	~20%
CASH CONVERSION ²	83%	100%+

ON TRACK TO DELIVER SIGNIFICANT POTENTIAL

1. Continuing operations / 2. Total Group / 3. Aftermarket changed from 60% to 50% to reflect the change of the Group's profile following Smiths Medical being accounted for as discontinued operations

smiths





COMPETITIVE STRENGTHS

- A strong presence in flow control for rotating equipment
- Strong proprietary technology and expertise in applied engineering
- Broad installed base
- Strong aftermarket service offering with c.200 sales and service centres
- Long-term customer relationships
- Margins at 20%+ through-cycle

GROWTH DRIVERS

- Oil & gas markets recovering driven by underlying energy demand
- Industrials market growth
- Expansion in high-growth markets
- Pent-up demand for maintenance and upgrades in oil & gas and petrochemical
- Need for operational improvements in non-oil and gas process industries
- Disruptive innovations including material science advancements and digital transformation

SMITHS DETECTION A GLOBAL LEADER IN THE DETECTION AND IDENTIFICATION OF SECURITY THREATS AND CONTRABAND £798m (32% of continuing Group revenue) £127_m (27% of continuing Group headline OP)

AFTERMARKET 46%

16.0%

COMPETITIVE STRENGTHS

MARGIN

- A global leader with differentiated technologies leveraged across markets
- Significant R&D capability
- Operating in several regulated markets requiring product certification
- Increasing digitisation and aftermarket revenue
- Long-term customer relationships
- Mid-teens + margin through-cycle

GROWTH DRIVERS

- Persistent and evolving terror threats
- Changing security regulations for air cargo and passengers
- Growing urbanisation and need to protect people and
- Global trade, e-commerce and passengers numbers
- Equipment replacement cycle, typically 7-10 years
- Growth of security infrastructure in emerging markets

FLEX-TEK INNOVATIVE COMPONENTS TO HEAT AND MOVE FLUIDS AND GASES £436m £84m (17% of continuing Group headline OP) MARGIN 19,2% AFTERMARKET 51%

COMPETITIVE STRENGTHS

- High-performance products
- Leading capability in design and manufacture
- Increasing pace of innovation
- Strong customer relationships
- Culture, safety and quality
- Mid-teens + margin through-

GROWTH DRIVERS

- Through-cycle growth of US housing construction
- Continued increase in large commercial aircraft production
- International expansion

SMITHS INTERCONNECT SOLUTIONS FOR HIGH-SPEED, SECURE CONNECTIVITY IN DEMANDING APPLICATIONS £319_m (13% of continuing Group revenue) HEADLINE OP £47_m (10% of continuing Group headline OP) MARGIN 14.7%

COMPETITIVE STRENGTHS

- Innovative and technically differentiated offerings
- Ultra-high reliability solutions used in demanding applications
- Strong research and engineering capabilities
- Customer intimacy, responsiveness and product customisation
- Global presence, reach and support
- Mid-teens + margin through-cycle

GROWTH DRIVERS

- Increased connectivity
- Growing urbanised population requiring transports and infrastructure
- Increasing geopolitical uncertainty
- Ageing population and rising need for healthcare services

SMITHS MEDICAL IS NOW ACCOUNTED FOR AS DISCONTINUED OPERATIONS REFLECTING THE PLANNED SEPARATION BY END OF H1 CY2020

SMITHS MEDICAL REVENUE £874_m OPERATING PROFIT £147_m MARGIN 16.8% CONSUMABLES 83%

COMPETITIVE STRENGTHS

- Category leader in our chosen markets
- Trusted brands with a reputation for quality and
- Strong, defensible intellectual property
- Over 80% of revenue is from single-use devices and proprietary consumables
- Strong customer relationships and extensive global sales network
- Margins 20%+ through-cycle

GROWTH DRIVERS

- Ageing populations with increasing personalised healthcare and patient expectation/quality of life
- Increasing incidence of chronic diseases
- Increasing need for connected systems and data analytics
- Growth of alternate site and home-based healthcare
- Growing healthcare spend in developing markets

Andy Reynolds Smith

CFO:

John Shipsey

Investor Relations:

investor.relations @smiths.com

Smiths Group plc

11-12 St James's Square London SW1Y4LB

LSE: SMIN **ADR OTC: SMGZY**